Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG.

Molecules. 2019 May 12;24(9). pii: E1825. doi: 10.3390/molecules24091825.

2.

Natural Docosahexaenoic Acid in the Triglyceride Form Attenuates In Vitro Microglial Activation and Ameliorates Autoimmune Encephalomyelitis in Mice.

Mancera P, Wappenhans B, Cordobilla B, Virgili N, Pugliese M, Rueda F, Espinosa-Parrilla JF, Domingo JC.

Nutrients. 2017 Jun 30;9(7). pii: E681. doi: 10.3390/nu9070681.

3.

Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes in Response to Omega-3 Supplementation: A Dose-Response Pilot Study.

Drobnic F, Rueda F, Pons V, Banquells M, Cordobilla B, Domingo JC.

J Lipids. 2017;2017:1472719. doi: 10.1155/2017/1472719. Epub 2017 Jun 1.

4.

Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines.

Rueda F, Eich C, Cordobilla B, Domingo P, Acosta G, Albericio F, Cruz LJ, Domingo JC.

Immunobiology. 2017 Nov;222(11):989-997. doi: 10.1016/j.imbio.2017.06.002. Epub 2017 Jun 10.

PMID:
28624137
5.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9.

PMID:
28181470
6.

Targeting the Brain with Nanomedicine.

Rueda F, Cruz LJ.

Curr Pharm Des. 2017;23(13):1879-1896. doi: 10.2174/1381612822666161221153228. Review.

PMID:
28003011
7.

Combinatorial prospects of nano-targeted chemoimmunotherapy.

Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ.

Biomaterials. 2016 Mar;83:308-20. doi: 10.1016/j.biomaterials.2016.01.006. Epub 2016 Jan 9. Review.

PMID:
26796043
8.

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.

Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CW, Ossendorp F.

J Control Release. 2014 Oct 28;192:209-18. doi: 10.1016/j.jconrel.2014.07.040. Epub 2014 Jul 25.

PMID:
25068703
9.

Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.

Cruz LJ, Rueda F, Simón L, Cordobilla B, Albericio F, Domingo JC.

Nanomedicine (Lond). 2014 Apr;9(4):435-49. doi: 10.2217/NNM.13.66.

PMID:
24910875
10.

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Review.

PMID:
23148541
11.

Targeting nanoparticles to dendritic cells for immunotherapy.

Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG.

Methods Enzymol. 2012;509:143-63. doi: 10.1016/B978-0-12-391858-1.00008-3. Review.

PMID:
22568905
12.

Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy.

Cruz LJ, Rueda F, Cordobilla B, Simón L, Hosta L, Albericio F, Domingo JC.

Mol Pharm. 2011 Feb 7;8(1):104-16. doi: 10.1021/mp100178k. Epub 2010 Dec 20.

PMID:
21121669
13.

Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids.

Zapata-Gonzalez F, Rueda F, Petriz J, Domingo P, Villarroya F, Diaz-Delfin J, de Madariaga MA, Domingo JC.

J Leukoc Biol. 2008 Oct;84(4):1172-82. doi: 10.1189/jlb.1007688. Epub 2008 Jul 16.

PMID:
18632990
15.

Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8.

Martí F, Bertran E, Llucià M, Villén E, Peiró M, Garcia J, Rueda F.

J Leukoc Biol. 2002 Sep;72(3):590-7.

PMID:
12223528

Supplemental Content

Loading ...
Support Center